Innovating cancer therapeutics, AlpENa Biosciences develops bispecific antibodies that activate immune cells to target and destroy tumor cells. Their research, based on the work of Professor Marjolein van Egmond, shows promising potential in a variety of oncology treatments. The company is backed by Versant Ventures in order to advance these therapies.